+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Microbiome Therapeutics Market - Global Forecast 2026-2032- Product Image
Microbiome Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Microbiome Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 183 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5674221
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Microbiome Therapeutics Market is projected to reach USD 669.68 Million in 2026. It is expected to continue growing at a CAGR of 26.35%, reaching USD 2.73 Billion by 2032.

Microbiome therapeutics are moving from exploratory science into regulated medicine, led by live biotherapeutic products, fecal microbiota-based therapies, defined microbial consortia, postbiotics, engineered strains, and targeted small molecules that modulate host-microbe pathways. The strongest clinical validation is in recurrent Clostridioides difficile infection, where the U.S. FDA approved the first fecal microbiota-based and orally administered microbiota-based therapies in 2022 and 2023, establishing a regulatory precedent for microbiota-based drug development.

For biopharmaceutical leaders, the opportunity is expanding beyond gastrointestinal disease into immunology, oncology support, metabolic disorders, liver disease, neurology, and women’s health. Success increasingly depends on validated biomarkers, reproducible manufacturing, donor or strain traceability, cold-chain and stability controls, and clinical endpoints that demonstrate durable patient benefit while meeting medicine-grade safety standards.

Transformative Shifts in the Microbiome Therapeutics Landscape

The microbiome therapeutics landscape is being reshaped by regulatory maturation, clinical selectivity, and a shift from broad fecal microbiota transfer toward defined microbial consortia and mechanism-led drug candidates. Developers are prioritizing indications with measurable dysbiosis, strong biological rationale, and clear unmet need rather than pursuing microbiome modulation as a generalized wellness claim.

Manufacturing is also transforming. Sponsors must prove identity, purity, potency, viability, and batch consistency while controlling contamination risk. This is pushing the sector toward GMP-grade anaerobic production, standardized donor screening, genomic characterization, validated potency assays, and scalable formulation technologies that can support capsules, rectal delivery, lyophilized products, and next-generation engineered strains.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding the value of metagenomics, metabolomics, transcriptomics, proteomics, and clinical datasets by helping identify microbial signatures, predict patient response, and prioritize therapeutic consortia. In practice, AI is accelerating strain selection, functional pathway mapping, adverse event signal detection, trial enrichment, and biomarker discovery for patients most likely to benefit.

The cumulative impact is not automation alone; it is better decision quality across discovery, development, manufacturing, and commercialization. However, AI models require transparent validation, diverse datasets, explainability, privacy controls, and regulatory-grade documentation. Industry leaders that combine machine learning with prospective clinical evidence will be better positioned to move microbiome therapeutics from association-based claims to mechanism-supported interventions.

Key Regional Insights for Microbiome Therapeutics

North America remains the most clinically advanced region for microbiome therapeutics, supported by U.S. FDA approvals, mature clinical-trial infrastructure, academic microbiome centers, and a high burden of recurrent Clostridioides difficile infection linked to antibiotic exposure and healthcare-associated infections. The United States anchors trial activity and early commercialization, while Canada contributes through hospital networks, public health surveillance, and translational microbiome research.

Europe benefits from strong translational science, biobanking infrastructure, antimicrobial resistance programs, and coordinated European Union oversight for advanced therapies and medicinal products, although reimbursement pathways remain country-specific. Asia-Pacific is gaining momentum through China, Japan, South Korea, India, and Australia, where sequencing capacity, chronic disease burden, digital health adoption, and biologics manufacturing capabilities support clinical development. Latin America, led by Brazil and Mexico, is emerging through clinical collaborations, infectious disease expertise, and expanding specialty care access. The Middle East is advancing through genomics programs, precision medicine investment, and tertiary care expansion, while Africa remains at an earlier stage but has rising relevance due to infectious disease burden, antimicrobial resistance priorities, and the need for locally representative microbiome datasets.

Key Group Insights Across Global Market Alliances

The European Union is influential because its regulatory coordination, research funding, pharmacovigilance expectations, and data protection standards shape how microbiome therapeutics are evaluated, manufactured, and monitored. G7 markets provide the deepest mix of advanced healthcare infrastructure, reimbursement capacity, specialist clinicians, and clinical-trial ecosystems, making them critical for late-stage development and real-world evidence generation.

BRICS countries offer scale, biologic manufacturing capacity, growing genomics capabilities, and large patient populations for research expansion, especially in China, India, and Brazil. ASEAN markets are gaining relevance through regional healthcare modernization, medical tourism, infectious disease surveillance, and microbiome nutrition research. GCC countries are investing in national genomics, specialty care, biotechnology localization, and healthcare diversification, while NATO markets overlap heavily with high-income clinical research geographies that support resilient supply chains, regulatory cooperation, and secure biomanufacturing networks.

Key Country Insights Shaping Market Expansion

The United States leads commercialization because of FDA precedent, specialized clinical investors, advanced sequencing capacity, and a large infectious disease treatment base. Canada supports evidence generation through academic hospitals, microbiome research programs, and coordinated healthcare data systems, while Mexico and Brazil provide expanding clinical access, gastroenterology expertise, and regional relevance in Latin America. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine advanced research hospitals, strong life-science clusters, and experience in regulated biologics, while Russia remains more constrained by geopolitical, funding, and regulatory complexity.

China is building scale in genomics, clinical research, and biomanufacturing; India offers a large patient base, cost-competitive clinical operations, and growing biotechnology capacity; Japan emphasizes quality systems, aging-related disease needs, and regulatory rigor; Australia contributes high-quality translational research and well-structured clinical trials; and South Korea combines biotechnology investment, hospital digitization, and advanced digital health infrastructure to support microbiome therapeutic development.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize indications with validated biology, feasible endpoints, and clear payer relevance. Recurrent Clostridioides difficile infection provides a proven starting point, but durable differentiation will come from patient stratification, mechanistic biomarkers, and evidence that microbiome modulation improves outcomes beyond standard care.

Executives should invest early in GMP manufacturing, strain characterization, donor screening where applicable, stability testing, potency assays, pharmacovigilance, and regulatory engagement. Partnerships with academic centers, sequencing platforms, AI specialists, contract manufacturers, and hospital networks can accelerate evidence generation, while disciplined pricing, reimbursement, and real-world evidence strategies will be essential for converting scientific promise into scalable adoption.

Research Methodology

This executive summary is based on triangulation of public regulatory records, peer-reviewed microbiome research, clinical-trial registries, health agency guidance, patent and policy signals, and macroeconomic healthcare indicators. Key reference areas include FDA actions on microbiota-based therapies, WHO and CDC antimicrobial resistance priorities, NIH-supported microbiome science, European regulatory guidance, and regional life-science policy developments.

The methodology emphasizes verified signals over speculative forecasts. Evidence was assessed across clinical validation, regulatory maturity, manufacturing readiness, geographic adoption, partnership activity, technology enablement, and healthcare system preparedness. Insights were synthesized to support strategic decision-making for biopharmaceutical, diagnostics, healthcare, and investment stakeholders.

Conclusion

Microbiome therapeutics are entering a decisive phase in which scientific novelty must be matched by clinical reproducibility, regulatory discipline, and manufacturing reliability. Approved microbiota-based therapies have validated the category, but the next wave will depend on defined mechanisms, patient selection, safety monitoring, and measurable long-term benefit.

Organizations that combine high-quality biological data, AI-enabled discovery, robust GMP production, validated biomarkers, and evidence-based market access strategies will be best positioned to lead. The future of microbiome therapeutics will favor developers that treat the microbiome not as a trend, but as a regulated therapeutic platform capable of addressing complex disease biology.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Microbiome Therapeutics Market, by Products
7.1. Introduction
7.2. Fecal Microbiota Transplantation
7.3. Live-Biotherapeutics
7.4. Microbiome Drugs
7.5. Microbiome Ecosystem Therapies
7.6. Probiotics & Prebiotics
8. Microbiome Therapeutics Market, by Therapeutic Area
8.1. Introduction
8.2. Autoimmune Diseases
8.3. Cancer
8.4. Gastrointestinal Disorders
8.5. Infectious Diseases
8.6. Metabolic Disorders
8.7. Neurological Disorders
9. Microbiome Therapeutics Market, by Formulation
9.1. Introduction
9.2. Oral
9.3. Topical
10. Microbiome Therapeutics Market, by Source
10.1. Introduction
10.2. Animal Microbiome
10.3. Environmental Microbiome
10.4. Human Microbiome
11. Microbiome Therapeutics Market, by End-use
11.1. Introduction
11.2. Academic & Research Institutions
11.3. Hospitals & Clinics
12. Microbiome Therapeutics Market, by Distribution Channel
12.1. Introduction
12.2. Offline
12.2.1. Hospital Pharmacies
12.2.2. Retail Pharmacies
12.3. Online Pharmacies
13. Microbiome Therapeutics Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Microbiome Therapeutics Market, by Group
14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. ASEAN
14.6. GCC
15. Microbiome Therapeutics Market, by Country
15.1. China
15.2. United States
15.3. Japan
15.4. India
15.5. Germany
15.6. United Kingdom
15.7. Australia
15.8. France
15.9. South Korea
15.10. Italy
15.11. Canada
15.12. Russia
15.13. Brazil
15.14. Mexico
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Alveolus Bio, Inc. by ResBiotic
17.2. AOBiome LLC
17.3. Assembly Biosciences, Inc.
17.4. Axial Therapeutics, Inc.
17.5. BioGaia AB
17.6. BiomeBank
17.7. EnteroBiotix Ltd
17.8. Enterome SA
17.9. Ferring B.V.
17.10. Intralytix, Inc.
17.11. Kanvas Biosciences
17.12. Locus Biosciences, Inc.
17.13. MaaT Pharma SA
17.14. Microba Life Sciences Limited
17.15. Microbiotica Ltd.
17.16. MRM Health NV
17.17. NuBiyota
17.18. Osel, Inc.
17.19. Pendulum Therapeutics
17.20. PharmaBiome AG
17.21. Pylum Biosciences
17.22. Seres Therapeutics, Inc.
17.23. Servatus Limited
17.24. Siolta Therapeutics
17.25. Theriva Biologics, Inc.
17.26. Vedanta Biosciences, Inc.
17.27. Viome Life Sciences, Inc. by BlueDot LLC
17.28. Xbiome Co. Ltd.
List of Figures
FIGURE 1. GLOBAL MICROBIOME THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL MICROBIOME THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL MICROBIOME THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL MICROBIOME THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
FIGURE 9. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL MICROBIOME THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL MICROBIOME THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL MICROBIOME THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL FECAL MICROBIOTA TRANSPLANTATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL FECAL MICROBIOTA TRANSPLANTATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL FECAL MICROBIOTA TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL LIVE-BIOTHERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL LIVE-BIOTHERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL LIVE-BIOTHERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL MICROBIOME DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL MICROBIOME DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL MICROBIOME DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL MICROBIOME ECOSYSTEM THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL MICROBIOME ECOSYSTEM THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL MICROBIOME ECOSYSTEM THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL PROBIOTICS & PREBIOTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL PROBIOTICS & PREBIOTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL PROBIOTICS & PREBIOTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL GASTROINTESTINAL DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL GASTROINTESTINAL DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL GASTROINTESTINAL DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL ANIMAL MICROBIOME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL ANIMAL MICROBIOME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL ANIMAL MICROBIOME MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL ENVIRONMENTAL MICROBIOME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL ENVIRONMENTAL MICROBIOME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL ENVIRONMENTAL MICROBIOME MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2017-2032 (USD MILLION)
TABLE 78. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 79. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 80. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 81. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2017-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 84. EUROPE MICROBIOME THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. EUROPE MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2017-2032 (USD MILLION)
TABLE 86. EUROPE MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 87. EUROPE MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 88. EUROPE MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 89. EUROPE MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2017-2032 (USD MILLION)
TABLE 90. EUROPE MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 91. EUROPE MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 92. NORTH AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. NORTH AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2017-2032 (USD MILLION)
TABLE 94. NORTH AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 95. NORTH AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 96. NORTH AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 97. NORTH AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2017-2032 (USD MILLION)
TABLE 98. NORTH AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 99. NORTH AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 100. LATIN AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. LATIN AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2017-2032 (USD MILLION)
TABLE 102. LATIN AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 103. LATIN AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 104. LATIN AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 105. LATIN AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2017-2032 (USD MILLION)
TABLE 106. LATIN AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 107. LATIN AMERICA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 108. AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2017-2032 (USD MILLION)
TABLE 110. AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 111. AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 112. AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 113. AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2017-2032 (USD MILLION)
TABLE 114. AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 115. AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 116. MIDDLE EAST MICROBIOME THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. MIDDLE EAST MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2017-2032 (USD MILLION)
TABLE 118. MIDDLE EAST MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 119. MIDDLE EAST MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 120. MIDDLE EAST MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 121. MIDDLE EAST MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2017-2032 (USD MILLION)
TABLE 122. MIDDLE EAST MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 123. MIDDLE EAST MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 125. NATO MICROBIOME THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 126. NATO MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2017-2032 (USD MILLION)
TABLE 127. NATO MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 128. NATO MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 129. NATO MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 130. NATO MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2017-2032 (USD MILLION)
TABLE 131. NATO MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 132. NATO MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 133. G7 MICROBIOME THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 134. G7 MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2017-2032 (USD MILLION)
TABLE 135. G7 MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 136. G7 MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 137. G7 MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 138. G7 MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2017-2032 (USD MILLION)
TABLE 139. G7 MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 140. G7 MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 141. BRICS MICROBIOME THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 142. BRICS MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2017-2032 (USD MILLION)
TABLE 143. BRICS MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 144. BRICS MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 145. BRICS MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 146. BRICS MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2017-2032 (USD MILLION)
TABLE 147. BRICS MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 148. BRICS MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 149. EUROPEAN UNION MICROBIOME THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 150. EUROPEAN UNION MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2017-2032 (USD MILLION)
TABLE 151. EUROPEAN UNION MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 152. EUROPEAN UNION MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 153. EUROPEAN UNION MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 154. EUROPEAN UNION MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2017-2032 (USD MILLION)
TABLE 155. EUROPEAN UNION MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 156. EUROPEAN UNION MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 157. ASEAN MICROBIOME THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 158. ASEAN MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2017-2032 (USD MILLION)
TABLE 159. ASEAN MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 160. ASEAN MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 161. ASEAN MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 162. ASEAN MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2017-2032 (USD MILLION)
TABLE 163. ASEAN MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 164. ASEAN MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 165. GCC MICROBIOME THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 166. GCC MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2017-2032 (USD MILLION)
TABLE 167. GCC MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 168. GCC MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 169. GCC MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 170. GCC MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2017-2032 (USD MILLION)
TABLE 171. GCC MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 172. GCC MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 173. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 174. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 175. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2017-2032 (USD MILLION)
TABLE 176. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 177. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 178. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 179. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2017-2032 (USD MILLION)
TABLE 180. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 181. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 182. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 183. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2017-2032 (USD MILLION)
TABLE 184. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 185. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 186. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 187. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2017-2032 (USD MILLION)
TABLE 188. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 189. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 190. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 191. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2017-2032 (USD MILLION)
TABLE 192. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 193. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 194. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 195. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2017-2032 (USD MILLION)
TABLE 196. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 197. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 198. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 199. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2017-2032 (USD MILLION)
TABLE 200. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 201. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 202. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 203. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2017-2032 (USD MILLION)
TABLE 204. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 205. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 206. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 207. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2017-2032 (USD MILLION)
TABLE 208. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 209. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 210. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 211. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2017-2032 (USD MILLION)
TABLE 212. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 213. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 214. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 215. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2017-2032 (USD MILLION)
TABLE 216. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 217. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 218. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 219. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2017-2032 (USD MILLION)
TABLE 220. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 221. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 222. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 223. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2017-2032 (USD MILLION)
TABLE 224. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 225. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 226. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 227. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2017-2032 (USD MILLION)
TABLE 228. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 229. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 230. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 231. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2017-2032 (USD MILLION)
TABLE 232. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 233. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 234. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 235. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2017-2032 (USD MILLION)
TABLE 236. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 237. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 238. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 239. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2017-2032 (USD MILLION)
TABLE 240. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 241. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 242. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 243. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2017-2032 (USD MILLION)
TABLE 244. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 245. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 246. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 247. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2017-2032 (USD MILLION)
TABLE 248. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 249. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 250. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 251. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2017-2032 (USD MILLION)
TABLE 252. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 253. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 254. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 255. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2017-2032 (USD MILLION)
TABLE 256. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 257. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 258. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 259. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2017-2032 (USD MILLION)
TABLE 260. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 261. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 262. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 263. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2017-2032 (USD MILLION)
TABLE 264. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 265. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 266. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 267. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2017-2032 (USD MILLION)
TABLE 268. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 269. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 270. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 271. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2017-2032 (USD MILLION)
TABLE 272. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 273. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 274. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 275. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2017-2032 (USD MILLION)
TABLE 276. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 277. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 278. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 279. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2017-2032 (USD MILLION)
TABLE 280. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 281. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 282. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 283. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2017-2032 (USD MILLION)
TABLE 284. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 285. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 286. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 287. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2017-2032 (USD MILLION)
TABLE 288. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 289. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 290. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 291. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2017-2032 (USD MILLION)
TABLE 292. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 293. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 294. GLOBAL MICROBIOME THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 295. GLOBAL MICROBIOME THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Alveolus Bio, Inc. by ResBiotic
  • AOBiome LLC
  • Assembly Biosciences, Inc.
  • Axial Therapeutics, Inc.
  • BioGaia AB
  • BiomeBank
  • EnteroBiotix Ltd
  • Enterome SA
  • Ferring B.V.
  • Intralytix, Inc.
  • Kanvas Biosciences
  • Locus Biosciences, Inc.
  • MaaT Pharma SA
  • Microba Life Sciences Limited
  • Microbiotica Ltd.
  • MRM Health NV
  • NuBiyota
  • Osel, Inc.
  • Pendulum Therapeutics
  • PharmaBiome AG
  • Pylum Biosciences
  • Seres Therapeutics, Inc.
  • Servatus Limited
  • Siolta Therapeutics
  • Theriva Biologics, Inc.
  • Vedanta Biosciences, Inc.
  • Viome Life Sciences, Inc. by BlueDot LLC
  • Xbiome Co. Ltd.

Table Information

Report AttributeDetails
No. of Pages183
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 669.68 Million
Forecasted Market Value ( USD ) by 2032 $ 2730 Million
Compound Annual Growth Rate26.3%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Human Microbiome Market - Global Forecast 2026-2032 - Product Image

Human Microbiome Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Microbiome Diagnostics Market - Global Forecast 2026-2032 - Product Image

Microbiome Diagnostics Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Microbiome Therapeutics - Global Strategic Business Report - Product Image

Microbiome Therapeutics - Global Strategic Business Report

  • Report
  • 148 Pages
  • Global
From
Live Biotherapeutic Products and Microbiome CDMO - Global Strategic Business Report - Product Image

Live Biotherapeutic Products and Microbiome CDMO - Global Strategic Business Report

  • Report
  • 108 Pages
  • Global
From
Human Microbiome Market (5th Edition): Industry Trends and Global Forecasts, till 2035 - Distribution by Type of Product, Type of Biologic, Route of Administration, Drug Formulation, Target Indication, Target Therapeutic Area and Geographical Regions - Product Image

Human Microbiome Market (5th Edition): Industry Trends and Global Forecasts, till 2035 - Distribution by Type of Product, Type of Biologic, Route of Administration, Drug Formulation, Target Indication, Target Therapeutic Area and Geographical Regions

  • Report
  • 552 Pages
  • Global
From

About the Microbiome Market

The Microbiome market is a subset of the biotechnology industry that focuses on the study of microbial communities and their interactions with the environment. It is a rapidly growing field, with research and development activities focusing on the development of new products and services that can be used to improve human health and the environment. Microbiome-based products and services are used in a variety of industries, including pharmaceuticals, food and beverage, agriculture, and cosmetics. The Microbiome market is driven by the increasing demand for personalized medicine, as well as the need for more efficient and cost-effective treatments for various diseases. Additionally, the development of new technologies, such as next-generation sequencing and metagenomics, has enabled researchers to better understand the composition and function of microbial communities. Companies in the Microbiome market include Second Genome, uBiome, Seres Therapeutics, and Enterome Bioscience. These companies are focused on developing products and services that can be used to improve human health and the environment. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.